PTPRC and neoplasm: MIH1 binding to tumor cells was reduced in a dose-dependent fashion from the vehicle group (80% of CD45- cells positive for MIH1) to 30 mg/kg CCX559 (3.8% of cells positive), and similarly in the MEDI4736 tumors compared to isotype (Fig 5C).